Skip to main navigation
Skip to main content

 

Skip to content
  • HOME
  • ABOUT
    VBL
    • COMPANY OVERVIEW
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • CANCER
    PROGRAMS
    • CANCER PLATFORM & TECHNOLOGY
    • PUBLICATIONS
  • INFLAMMATION
    PROGRAMS
    • INFLAMMATORY PLATFORM
    • INFLAMMATORY PIPELINE
    • PUBLICATIONS
  • VB-600
    PLATFORM
    • OVERVIEW
    • TARGETING MOSPD2 FOR INFLAMMATION
    • TARGETING MOSPD2 FOR CANCER
    • PUBLICATIONS
  • PATIENTS &
    CAREGIVERS
    • CLINICAL TRIALS
    • COMPASSIONATE USE
  • INVESTOR
    RELATIONS
    • IR HOMEPAGE
    • PRESS RELEASES
    • EVENTS AND PRESENTATIONS
    • STOCK INFORMATION
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • INVESTOR FAQ & CONTACTS
About_VBL_2

Investor Relations

  • IR HOMEPAGE
  • PRESS RELEASES
  • EVENTS AND PRESENTATIONS
  • STOCK INFORMATION
  • ANALYST COVERAGE
  • SEC FILINGS
  • CORPORATE GOVERNANCE
  • INVESTOR FAQ & CONTACTS

Investor Relations

SEC Filing Details

Document Details

Form
CORRESP
Filing Date
Jan 6, 2021
Document Date
Jan 6, 2021
Form Description
CORRESP
Filing Group
Other
Company
VBL Therapeutics
Issuer
Vascular Biogenics Ltd.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • RSS
  • E-mail Alerts
  • Investor Contacts
Copyright © 2014 VBL All rights reserved
  • TERMS AND CONDITIONS
  • PRIVACY
  • CONTACT US
Design by: Berliner Design   |  Site by: foothold-systems
Print Friendly